Bevacizumab and Fotemustine for Recurrent Glioblastoma: A Phase II Study of AINO (Italian Association of Neuro-Oncology)

Journal of Neuro-Oncology - Netherlands
doi 10.1007/s11060-013-1317-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients With Recurrent Glioblastoma in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Addition of Lomustine for Bevacizumab-Refractory Recurrent Glioblastoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2014English

Bevacizumab and Chemotherapy for Recurrent Glioblastoma: A Single-Institution Experience

Neurology
Neurology
2009English

Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Phase II Study of Bevacizumab and Vorinostat for Patients With Recurrent World Health Organization Grade 4 Malignant Glioma

Oncologist
Cancer ResearchMedicineOncology
2017English

Neuro-Oncology Practices in Australia: A Cooperative Group for Neuro-Oncology Patterns of Care Study

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2013English

Phase II Study of Bevacizumab and Preoperative Chemoradiation for Esophageal Adenocarcinoma

Journal of Gastrointestinal Oncology
OncologyGastroenterology
2016English

Sustained Focal Antitumor Activity of Bevacizumab in Recurrent Glioblastoma

Neurology
Neurology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy